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Abstract
Background: Huntington's Disease (HD) is an inherited autosomal dominant genetic disorder in
which neuronal tissue degenerates. The pathogenesis of the disease appears to center on the
development of protein aggregates that arise initially from the misfolding of the mutant HD protein.
Mutant huntingtin (Htt) is produced by HD genes that contain an increased number of glutamine
codons within the first exon and this expansion leads to the production of a protein that misfolds.
Recent studies suggest that mutant Htt can nucleate protein aggregation and interfere with a
multitude of normal cellular functions.
Results: As such, efforts to find a therapy for HD have focused on agents that disrupt or block the
mutant Htt aggregation pathway. Here, we report that short guanosine monotonic
oligonucleotides capable of adopting a G-quartet structure, are effective inhibitors of aggregation.
By utilizing a biochemical/immunoblotting assay as an initial screen, we identified a 20-mer, all G-
oligonucleotide (HDG) as an active molecule. Subsequent testing in a cell-based assay revealed that
HDG was an effective inhibitor of aggregation of a fusion protein, comprised of a mutant Htt
fragment and green fluorescent protein (eGFP). Taken together, our results suggest that a
monotonic G-oligonucleotide, capable of adopting a G-quartet conformation is an effective
inhibitor of aggregation. This oligonucleotide can also enable cell survival in PC12 cells
overexpressing a mutant Htt fragment fusion gene.
Conclusion: Single-stranded DNA oligonucleotides capable of forming stable G-quartets can
inhibit aggregation of the mutant Htt fragment protein. This activity maybe an important part of the
pathogenecity of Huntington's Disease. Our results reveal a new class of agents that could be
developed as a therapeutic approach for Huntington's Disease.
Background
Huntington's Disease (HD) is an inherited disorder
caused by expansions of CAG repeats (polyglutamine-
polyQ) at the N-terminus, within exon 1, of the HD pro-
tein. The extent of polyglutamine expansion is correlated
with the severity of the symptoms and their onset [1]
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while the pathology of the disease and neuronal cell death
are thought to be associated with protein misfolding and
protein aggregation. These aggregates are usually seen in
the nucleus but can also be found in the cytoplasm [2].
Protein aggregates develop via a complex biochemical
process with intermediates being visible during the proc-
ess. PolyQ tracts within the pathogenic range induce a
protein insolubility whereas Htt with nonpathogenic
length maintains a measured degree of solubility [3,4].
Consistent with the aggregate toxicity hypothesis, inhibi-
tion of aggregate formation has been shown to have ben-
eficial effects on the progression of HD in the R6/2 mouse
model [5]. The implication of the polyQ aggregates in
cytotoxicity validates them as targets for novel therapeu-
tics. Despite the lack of details surrounding the molecular
structure of the polyQ aggregates, high throughput screen-
ing for compounds that inhibit their formation have pro-
duced some promising results. Several compounds,
including Congo Red [5] and Clioquinol [6], have been
reported to inhibit the aggregation process in the R6/2
mouse model but their neurotoxicity tempers enthusiasm.
Thus, identifying molecules that show efficacy with mini-
mal toxicity should be an important consideration in the
search for HD therapeutics.
Synthetic oligonucleotides (ODNs) provide a model cate-
gory of reagents that meet some of these requirements.
Oligonucleotides are synthetic polymers that are pro-
duced in highly purified quantities in a cost-effective way
and the technology surrounding ODN synthesis has
advanced dramatically in the last 10 years. Recently,
Parekh-Olmedo et al. (2004) showed that certain classes
of ODNs can inhibit aggregation. One of these groups is
the G-rich oligonucleotide (GROs) class which have been
used previously as aptamers to block protein function.
Specifically, GROs have been shown to bind directly to
STAT3 and interact with regions of the protein that enable
dimerization [7] and in another instance, GROs have
been shown to block the integration of the HIV into the
host chromosome by interacting with the HIV integrase
[8,9]. In both cases, the GRO forms a structure known as
a G-quartet which arises from the association of four adja-
cent G-bases assembled into a cyclic conformation. These
structures are stabilized by von Hoogstein hydrogen
bonding [10] and by base stacking interactions. These
molecules exhibit a very compact structure which allows
them to interact productively with functionally important
protein domains.
Much of the focus on developing therapeutics that block
aggregate formation comes from a wealth of data associat-
ing HD pathogenesis with the presence of cellular inclu-
sion bodies. But, recent evidence from in vitro [11-13] and
in vivo [14-16] studies suggest that Htt inclusions may not
be toxic to the cell or lead to neuronal degeneration. In
fact, Hayden and colleagues have created an exciting
mouse model that shows no long term effect of Htt inclu-
sions on behavior or viability [6]. It may be true that
inclusion bodies are neuroprotective and eliminating
them may actually increase the potential for neurotoxic-
ity.
Because of the known biological activity of GROs in inter-
acting with specific protein domains, we tested this type of
oligonucleotide in assays that measure the aggregation
activity of mutant Htt fragment. We report that G-rich oli-
gonucleotides, which form G-quartets, inhibit aggrega-
tion of mutant htt fragment in biochemical and cell-based
assays. Overall, our results suggest that G-rich oligonucle-
otides could be used to examine the relationship between
cellular aggregates and toxicity in various model systems.
Results
Biochemical analyses of GROs
The original observation that oligonucleotides bearing
random sequences reduced Htt aggregate formation [17]
prompted a closer examination of a potential role for
ODNs in HD therapy. We chose to utilize a biochemical/
immunochemical assay system that enables rapid screen-
ing of compounds/molecules for the inhibition of aggre-
gation [18]. In this test, oligonucleotides were mixed with
purified mutant Htt fragment for 24 hours and then
passed through a cellulose acetate membrane filter. The
percentage of aggregates remaining on the filter was
detected by immunochemistry using a primary Htt-anti-
body and a secondary anti-rabbit antibody conjugated to
peroxidase. Signals from the SDS insoluble aggregates
were scanned and quantified. A diagram of this assay,
established by Wang et al. (2005), is presented in Figure 1.
In all preparations of the mutant protein, thrombin-
directed cleavage of GST-Q58Htn was allowed to proceed
for 45 minutes prior to the addition of the GRO. This
cleavage generates an amino terminal polyglutamine frag-
ment consisting of 171 amino acids of the human hunt-
ingtin with tract of 58 glutamine residues [19]. The
fragment is fused to GST to enable purification. We will
utilize the Wang et al [19] terminology, GST-Q58-Htn to
designate the protein used in this assay. The mixture was
centrifuged to remove any aggregates that had already
formed. Western blot analyses have shown that >95% of
the GST-Q58-Htn is cleaved to completion by the
thrombin [see 19]. This parameter is an important control
for our study since a variety of agents are known to block
the enzymatic cleavage reaction directed by thrombin
[20].
Two known GROs were tested for inhibitory activity in the
biochemical assay described above. ODN T30923 and
ODN T40216 were designed by Jing et al. [7] and used asBMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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aptamers to inhibit the function of STAT3 protein. Both of
these molecules have been determined by Circular Dichr-
oism (CD) and NMR to have an intramolecular G-quartet
structure, and similar CD spectra were seen by our lab (see
below). The sequence of each is provided in Figure 2A;
T30923 contains (GGGT)4, 16 bases in length while
T40216 contains (GGGGGT)4, 24 bases in length.
These two GROs were tested in the biochemical screen for
inhibitory activity of Htt fragment aggregation. GST-Q58-
Htn was mixed with either T30923 or T40216 following
thrombin cleavage and centrifugation (see above) and
then incubated for 24 hours. Aggregation was stopped by
adding SDS and 2-mercaptoethanol and heating at 99°C.
The aggregates, retained on the membrane after filtration,
were quantitated following immunoblotting using an
image analyses program [see 19 and Material and Meth-
ods]. Three control reactions, designated 0-hour, 24-hour
and Congo Red (Figure 2B), were repeated for each exper-
iment. The 0-hour control displays the amount of aggre-
gation at the start of the reaction, usually none. The 24-
hour control reflects the amount of GST-Q58-Htn aggre-
gation when no inhibitor is added to the mixture. The
third control displays the degree of aggregation formed in
the presence of Congo Red, a known inhibitor [21] func-
tioning as the positive control in the series. As shown in
Figure 2B, both T40216 and T30923 are capable of inhib-
iting GST-Q58-Htn aggregation with a dose response visi-
Diagram of the biochemical model screening assay Figure 1
Diagram of the biochemical model screening assay. This diagram is taken from Wang et al. (2005) and illustrates the steps 
involved in the biochemical/immunoblotting assay used in this paper. The fusion protein GST-Q58-Htn (20 μg/ml) was mixed 
with thrombin (0.5 unit/μg protein) for 30 minutes and the mixture centrifuged to remove aggregated protein. The soluble 
protein was mixed with an oligonucleotide in a 96-well PCR plate and incubated for 24 hours at room temperature (RT). SDS 
was added to a final concentration of 2% and the mixture heated at 99°C for 5 minutes. Filtration through a 0.22 micron ace-
tate cellulose membrane filter was followed by detection of aggregated Q58-Htn fragment by immunoblotting with an antibody 
(HP1) and ECL. Quantitation was carried out using an ImageQuant program. The blot displays both positive and negative 
results – positions lacking a black spot indicate that aggregation was inhibited by the oligonucleotide.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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ble in the samples with T30923. Figure 3 represents the
results of five experiments conducted in duplicate, fol-
lowed by quantitation using ImageQuant analytical soft-
ware. A statistically significant difference is observed
between each GRO and the 24-hour control in each exper-
iment.
Oligonucleotide inhibition of aggregation of mutant Htt fragment Figure 2
Oligonucleotide inhibition of aggregation of mutant Htt fragment. (A) DNA sequence of two G-rich oligonucleotides 
that form the G-quartet structure. (B) Dot blot analysis of T40216 and T30923 activity on aggregation. The zero (0) hour con-
trol represents reactions that were stopped immediately after addition of the protein; 24-hour reactions carried out in the 
absence of the oligonucleotide and stopped after 24-hours of incubation; Congo red, level of aggregation 24 hours after addi-
tion of Congo Red (10 μM).BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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The effect of GROs on aggregation prompted an examina-
tion of the activity of a monotonic guanosine oligonucle-
otide (HDG) because this molecule can also form a G-
quartet. We chose 20 bases as a compromised length of
T30923 (16 bases) and T40216 (24 bases) to establish the
HDG series. When a dose range of HDG was tested in the
biochemical assay, inhibition of aggregation Q58-Htn
fragment was readily observed (Figure 4). A significant
decrease was seen at 1 μM, a much lower final concentra-
tion than the inhibitory level found with either T30923 or
T40216. HDG was found to be unique in its inhibitory
activity compared to other monotonic oligonucleotides.
Huang et al. [18] demonstrated that the flow-through frac-
tion of reactions containing inhibitors of aggregation is
comprised predominantly of monomeric Htt fragments.
To verify that the flow-through in reactions bearing HDG
20 contains mutant Htt fragments, we captured this frac-
tion and placed it on blotting paper. Stacked membranes
to capture monomers using the same antibody used to
detect aggregates. As seen in the inset for Figure 4, a posi-
tive reaction was observed indicating the presence of
mutant Htt fragment. When 20-mers of A (HDA), T
(HDT) or C (HDC) were tested at 20 μM and 40 μM, no
inhibition of aggregation was observed (Figure 5). Quan-
titation after scanning revealed a large, statistically signif-
icant difference in the activity of HDG compared to any of
the other monotonic ODNs (Figure 6). Taken together,
our results suggest that HDG, a 20-mer containing all G
residues, is a powerful inhibitor of aggregation of Q58-
Htn fragment based on the results of the immunoblotting
assay.
CD measures differences in the absorbance of right-
handed and left-handed circularly polarized light and can
be used to investigate DNA helicity. G-quadruplexes can
exist as antiparallel monomers, dimers or tetramers or as
parallel tetramers. Traditionally, antiparallel conforma-
tions are characterized by a positive ellipticity maximum
at 295 nm and a negative minimum at 265 nm. In con-
trast, the parallel conformation is characterized by a posi-
tive maximum at 264 nm and a negative minimum at 240
nm; however, recent results have shown some antiparallel
structures to have some positive maximums at 264 nm
and negative minimums at 240 nm [22-24]. HDG was
Graphic depiction of aggregation inhibition by GROs Figure 3
Graphic depiction of aggregation inhibition by GROs. Here, T40216 and T30923 and Congo Red are used: Data are pre-
sented from five independent reactions, as shown in (B) for each point with standard deviation. *, denotes significance p < 0.05 
as compared to Congo Red (control) as determined by a one way ANOVA with Tukey's post hoc test.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
Page 6 of 16
(page number not for citation purposes)
characterized by CD in order to gain a perspective view of
its structure. HDG was analyzed along with HDA and
T30923 at 15 μM in 10 mM KCl and at 24°C. CD spec-
tropolarity was determined using an AVIV Model 202
spectrometer with an effective range of analysis from 200
nm to 320 nm (Figure 7). HDA has an unusual maximum
absorbance at 220 nm with a smaller positive absorbance
at 260 nm. T30923 and HDG, however, exhibit maximum
positive absorbances at 264 nm and negative minimums
at 241 nm, a distinct profile that matches closely with
molecules known to adopt G-quartet structures. HDG is a
more effective inhibitor of GST-Q58-Htn aggregation
than T30923 which is known to adopt a dimer basket G-
quartet conformation [see 7] suggesting that HDG's struc-
ture is a more active conformation in our assays. Further
structural studies are ongoing.
Inhibition of aggregate formation in HEK293 cells
Since HDG exhibited strong inhibitory activity of GST-
Q58-Htn in a biochemical assay, we tested this molecule
in a cell-based assay. The human embryonic kidney cell
line HEK293 was transfected with plasmid pcDNA3.1-
72Httexon1-eGFP (p72Q), a construct that contains a
fusion gene uniting the first exon of the HD gene contain-
ing a polyQ repeat of 72 codons and the eGFP gene (J.
Pearson, unpublished data). This fragment of huntingtin
differs from GST-Q58-Htn in both length of poly-
glutamine stretch and that it is fused to eGFP rather than
GST. When transfected into HEK293 cells, the gene is
expressed and aggregates appear within 12 hours,
reflected by the appearance of discrete green foci. Cells
were photographed first under white light to verify that
equal numbers of cells were present for each treatment
HDG 20 inhibits aggregation of mutant Htt fragment Figure 4
HDG 20 inhibits aggregation of mutant Htt fragment. HDG 20, a 20-base monotonic G oligonucleotides was tested in the 
assay outlined in Figure 1 (see legend) at the indicated concentration. The reaction was carried out 4 times in duplicate for 24 
hours and a representative blot from the four independent experiments is shown. 0 hour, reaction mixture stopped at time 
zero; 24 hours, control reaction lacking oligonucleotides. (Inset), The Flow-through from filter binding reaction containing 
HDG 20 (20 μM or 40 μM) was placed on blotting paper, dried and processed as described in the legend to Figure 1.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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and a representative sample is shown. eGFP foci were then
imaged in the presence or absence of plasmid p72Q. In
Figure 8, green fluorescent foci are evident when p72Q is
present but a significant reduction is seen in cells that
have also received Congo Red. Importantly, inhibition of
aggregate formation is only partially inhibited when a
lower dosage of Congo Red is present, demonstrating a
dose-dependent effect. In Figure 9, a cell population in
which HDA was co-transfected with p72Q is presented;
HDA appears to have had little effect on the number of
aggregates formed in these cells. As is the case in the bio-
chemical assay (Figure 5), HDA does not appear to inhibit
aggregate formation in HEK293 cells. Figure 10 illustrates
the effect of HDG on aggregate formation. The white light
photograph again reveals that HDG has no detectable
toxic effect on cells or cell growth at 750 nM (top left
panel), but a clear dose effect is seen on the number of
aggregates when the level of HDG is increased (bottom
panels). These observations confirm results obtained in
the biochemical assay using HDG as the inhibitor. Finally,
in Figure 11, a panel of photographs reveals once again
that HDG is an effective inhibitor of aggregate formation
but that this positive activity can be reduced significantly
when T residues are inserted at the 7th and 14th position of
Specificity of monotonic oligonucleotides in the inhibition of mutant Htt fragment aggregation Figure 5
Specificity of monotonic oligonucleotides in the inhibition of mutant Htt fragment aggregation. Various monotonic 20-
mers were tested for inhibitory activity in the assay outlined in Figure 1. HDC, 20-mer with all Cs; HDA, 20-mer with all As; 
HDT, 20-mer with all T's; HDG, 20-mer with all Gs. Four independent experiments were carried out in duplicate and this blot 
is most representative of all of the results. 0 hour, reaction stopped at zero time point; 24 hour, reaction lacking oligonucle-
otides, stopped at 24 hours; Congo Red, incubation with 10 μM of Congo Red for 24 hours.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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the HDG 20-mer (HDG 20/7), every third base of the
HDG 20-mer (HDG 20/3) or every other base of the HDG
20-mer (HDG 20/2). To validate these results and to fur-
ther explore the relationship between the cell-based, and
biochemical assays, we assayed HDG 20/7, HDG 20/4
and HDG 20/3 individually for activity in the immunob-
lot assay (see Figure 2B). These results confirm the low
level of activity observed for HDG 20/7, HDG 20/3 and
HDG 20/2 respectively in the cell-based assay (Figure 12).
The correlation between the results obtained in the cell-
based and immunoblot assay reveal a similar mode of
action for the oligonucleotides. We have preliminary evi-
dence that the reduction in aggregates observed in the cell-
based assay can be confirmed when aggregates isolated
from transfected cells are passed through the immunoblot
assay (M. Skogen et al. in preparation).
Aggregate reduction in response to the addition of HDG
can also be seen using FACS analysis as the readout.
Again, HEK293 cells were transfected with p72Q with or
without HDG (or HDA) and the reactions were allowed to
proceed for 48 hours. The cells were then processed for
FACS and measured for green fluorescence. The Y axis
reflects the degree or intensity of fluorescence. As seen in
Figure 13A, the background is gated at the far left of the
graphic whereas expression of p72Q produces a sharp
peak of green fluorescence near the right edge of the pro-
file (Figure 13B). This peak represents aggregated Htt-
eGFP, scored by FACS as cells containing high intensity
eGFP (aggregates). In Figures 13C and 13D, the profile of
cells treated with HDA is represented and little detectable
change is observed in the peak at the far right edge. Even
as the level of HDA is increased from 1 μM to 2.5 μM, no
significant reduction in aggregates is observed. In contrast,
cells treated with HDG exhibit a very different profile (Fig-
ures 13E and 13F) as the peak representing aggregates is
diminished in a dose-dependent fashion. Thus, taken
together, the data suggest that HDG can inhibit aggrega-
tion formation in HEK293 cells expressing the Htt-eGFP
fusion protein from plasmid p72Q.
Finally, a derivative PC12 cell line, Htt14A2.6 [25], was
used to measure the capacity of HDG to improve cellular
viability. This neuronal cell line is used as a standard in
the field for studying the survival phenotype associated
with aggregate formation. In this assay, a truncated form
Graphic depiction of blots carried out to test monotonic 20-mers Figure 6
Graphic depiction of blots carried out to test monotonic 20-mers. Average aggregation levels, representative of 5 inde-
pendent experiments with standard deviation and average values (Series 1) presented. *, denotes significance p < 0.05 as com-
pared to Congo Red (control) as determined by a one way ANOVA with Tukey's post hoc test.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
Page 9 of 16
(page number not for citation purposes)
of Htt exon 1 (103Q) fused to enhanced green fluorescent
protein (eGFP) is induced to express by addition of muris-
terone to the culture. After induction, cell viability
decreases rapidly between 48 hours and 72 hours, respec-
tively, as measured by a CellTiter-Glo Luminescent cell
viability assay, as shown in Figure 14. The addition of
increasing doses of HDG (0.4 – 1.6 μg/μl) appears to
arrest the drop in viability providing some level of neuro-
protection. The differences in these are statistically signif-
icant and a larger, survival study is underway to confirm
and/or expand upon these results.
Discussions and conclusion
Intracellular aggregates of Htt have long been considered
phenotypic evidence of the neurodegenerative disorder
Huntington's Disease. It is, however, not clear how the
appearance of such inclusion bodies relates to the patho-
genesis of the disease. A number of model systems have
been designed to screen for therapeutic agents that can
inhibit aggregation. Some of these assays measure the
inhibition of fusion protein aggregation, proteins con-
taining a fragment of Htt (here, GST-Q58-Htn) and a
marker/reporter protein, often eGFP. The Htt component
of this fusion protein harbors an expanded polyQ stretch.
We have examined the capacity of G-rich oligonucleotides
that can adopt a G-quartet conformation to block aggrega-
tion. A well-established biochemical assay was used to
examine GROs blockage of aggregation. Molecules
T40216 and T30923 that are known to form intermolecu-
lar G-quartets were found to be effective inhibitors of
aggregation. Both of these GROs, which were used previ-
ously to inhibit Stat3, adopt conventional G-quartet struc-
ture with the G residues (quartets) in the center and a loop
domain at the top and bottom [7]. The GRO HDG, which
exhibits the highest level of activity in the aggregation
assays, can also adopt a stable G-quartet structure and fur-
ther studies to elucidate the details of the G-quartet struc-
CD spectroscopy of HDA and HDG Figure 7
CD spectroscopy of HDA and HDG. CD spectra of 15 μM HDG (heavy solid line), 15 μM T30923 (light solid line) and 15 
μM HDA (dotted line) in 10 mM KCl at 24°C.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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ture adopted by HDG are currently being performed. This
molecule also may prevent or delay neurotoxicity in PC12
cells.
The GRO, HDG, is unique among monotonic oligonucle-
otides containing 20 bases. None of the related 20-mers,
HDA, HDC or HDT show reproducible inhibitory activity
in the biochemical or cell-based assays. Furthermore,
HDG displays a dose response with concentrations as low
as 1 μM exhibiting substantial levels of aggregate reduc-
tion. It is effective when added at the start of the Q58-Htn
aggregation reaction but much less so when added after
the process has begun (Skogen et al., in preparation).
Thus, it is likely to block the nucleation phase of aggrega-
tion rather than the elongation phase, although our exper-
iments were not designed to discriminate between these
two phases [26,27].
HDG is also quite active in blocking aggregation of the
Httexon1-eGFP fusion protein aggregation in HEK293
cells. In this system, the fusion protein is produced from
an expression plasmid and co-transfection with HDG pre-
vents the appearance of green fluorescent foci in a dose-
dependent inhibition. Importantly, the well-known
aggregation inhibitor, Congo Red, was used as a positive
control and displayed effects similar to HDG. MTT viabil-
ity assays reveal no cell toxicity or negative effects on cell
growth as a function of oligonucleotide addition (data
not shown). This result is not surprising since ODNs used
as antisense or antigene therapy have been found to be
practically inert in human cells with regard to cytotoxicity.
A number of clinical trials using ODNs have taken place
and while the efficacy of such treatments may be ques-
tioned, significant adverse effects on cells or patients were
not observed. The lack of serious side effects from oligo-
nucleotides is a virtue in the development of these mole-
cules for use in HD patients. For example, while the
effective levels for GRO actvitiy presented in this work are
higher than those used for traditional pharmaceuticals,
oligonucleotides are particularly well-tolerated in
humans. The level herein is not unusual and levels exceed-
ing 50 mg/kg have been found to be both efficacious and
nontoxic in various antisense therapies. The higher
amounts may be required because delivery to target cells
or penetration into the cells may be less efficient than
other drug treatments.
Inhibition of aggregation in HEK 293 cells transfected with plasmid, pcDNA3.1-72Httexon1-eGFP (p72Q) Figure 8
Inhibition of aggregation in HEK 293 cells transfected with plasmid, pcDNA3.1-72Httexon1-eGFP (p72Q). Series of 
control reactions including HEK293 photographed under white light or in dark field, aggregate formation produced by p72Q 
and inhibition of aggregation by Congo red (0.2 μM or 1 μM) added concurrently with p72Q.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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The potency of the G-quartet structure of HDG is demon-
strated further in the activity of the modified HDGs. Using
a type of reverse genetics strategy, we created several
"mutant" HDGs; HDG 20/7 wherein each 7th  G was
replaced with a T, HDG 20/3 wherein each 3rd G was
replaced with a T and HDG 20/2 wherein every other G
was substituted with a T residue. None of these molecules
were found to be effective inhibitors of aggregation. The
results presented in Figure 11 most clearly illustrate the
importance of the HDG G-quartet structure while support
for this notion is also gained when T30923 could not fully
substitute for HDG in the HEK293 assay.
The mechanism by which HDG exhibits its effect in these
assays is not clear, but several paths can be suggested. G-
quartets created either by natural processes or by exoge-
nous addition, are reactive structures in the cell. They were
first recognized in studies aimed at understanding the
mechanism of cellular aging [28] occurring naturally near
the ends of chromosomes. These telomeric structures are
composed of repetitive blocks of the double-stranded
DNA sequence (TTAGGG)n with the guanines forming an
overhang at the end of the telomere. In humans, these
sequence blocks can become extremely long, increasing
the probability that they adopt secondary (G-quartet)
HDA was co-transfected at the indicated concentrations with p72Q and the cells were photographed 48 hours later in dark  field Figure 9
HDA was co-transfected at the indicated concentrations with p72Q and the cells were photographed 48 hours later in dark 
field.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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HDG was co-transfected at the indicated concentrations with p72Q and the cells were photographed 48 hours later in dark  field Figure 10
HDG was co-transfected at the indicated concentrations with p72Q and the cells were photographed 48 hours later in dark 
field.
The indicated ODN was co-transfected with p72Q and the cells photographed 48 hours later under dark field Figure 11
The indicated ODN was co-transfected with p72Q and the cells photographed 48 hours later under dark field. The upper left 
panel represents a reaction lacking oligonucleotide.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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structures. Such structures are known to inhibit telomer-
ase activity and may explain why telomerase replication/
activity in transformed cells is often absent or reduced
[29,30].
G-quartets formed within GROs have also been shown to
inhibit protein dimerization of such molecules as STAT3
[7]. They exert their activity by binding to specific
domains within STAT3 with a high degree of precision.
Since mutant Htt aggregation relies on a nucleation phase
in which the mutant protein begin to assemble, HDG
could block the transition between nucleation and elon-
gation as aggregation (dimerization) begins. Alterna-
tively, HDG could block other enzymes involved in the
development of the pathogenic phenotype, such as cas-
pases which cleave the native protein perhaps producing
a toxic fragment [31,32]. Bates and colleagues have shown
that certain GROs can bind to nucleolin in a variety of
cancer cells with a high degree of specificity [33]. In all of
these cases, direct interactions with cellular proteins
would be required and such a reaction is a well-docu-
mented characteristic of GROs. Studies are now underway
to determine which proteins are binding to HDG and if
there is a difference between the composition of protein-
GRO complexes in mutant and wild-type cells.
Methods
Biochemical aggregation assay
To analyze the inhibition of aggregation by GROs, a bio-
chemical assay was employed (Figure 1). The fusion pro-
tein GST-Q58-Htn [19] was incubated for 45 minutes at
room temperature with thrombin (1 U/1 μg protein) at a
concentration of 10 μg/ml in a buffer of 50 mM Tris-HCl,
pH 8, 100 mM NaCl, 2.5 mM CaCl2, and 1 mM EDTA, to
cleave between the huntingtin and GST. As indicated by
Wang et al. [19], this fragment consists of the amino ter-
minal 171 amino acids with a tract of 58 glutamine resi-
dues fused to GST. The protein mix was then centrifuged
at 30,000 × g at 4°C for 35 minutes to remove any aggre-
gates that had already formed. The protein was added to
wells containing 0.5–60 μM GROs or control ODNs, 10
μM Congo Red, or no treatment in the buffer detailed
above with 100 mM KCl replacing NaCl. The 0-hour con-
trol was stopped immediately and after 24 hours incuba-
tion at room temperature the remaining reactions were
stopped by adding 10% SDS/50 mM 2-mercaptoethanol
and heating to 99°C for five minutes. The mixture was
diluted in 1X PBS and then filtered through a cellulose
acetate membrane (Osmonics) using the Easy-Titer ELIFA
system (Pierce) followed by a 2% SDS wash. After block-
ing in 5% milk/1X PBS-0.05% Tween, the membrane was
incubated with a specific anti-huntingtin antibody (HP1,
1:1000 dilution), followed by incubation with a peroxi-
dase-conjugated goat anti-rabbit antibody (Sigma,
1:40,000 dilution) and chemiluminescence reagent (ECL-
Plus, Amersham). Signals from the aggregates retained on
the filter were scanned and quantified using ImageQuant
image analysis software (Molecular Dynamics). Aggre-
gates were quantified by optical density and statistical dif-
ferences were determined by one way ANOVA with
Various 20-mers with thymine modifications were tested for  inhibitory activity in the assay outlined in Figure 1 Figure 12
Various 20-mers with thymine modifications were tested for 
inhibitory activity in the assay outlined in Figure 1. HDT, 20-
mer with all T's; HDG, 20-mer with all G's; HDG 20/7, 20-
mer with every 7th nucleotide replaced with T; HDG 20/4, 
20-mer with every 4th nucleotidereplaced with T HDG 20/3, 
20-mer with every 3rd nucleotide replaced with T; HDG 20/
2, 20-mer with every other nucleotide replaced with T. 0 
hour, reaction stopped at zero time point; 24 hour, reaction 
lacking oligonucleotide and reaction stopped at 24 hours; 
Congo Red, incubation with Congo Red (10 μM) for 24 
hours.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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Tukey's post hoc analysis using Statistical Package for the
Social Sciences (SPSS). Significance was determined by a p
< 0.05 as compared to Congo Red (control).
HEK-293T cell-based aggregation assay
Human embryonic kidney cells, HEK293T, were grown in
low glucose DMEM supplemented with 10% FBS. Cells
were seeded at 0.5 – 1 × 106 cells/well on 6-well plates.
The cells were transfected with 1 μg of the plasmid
pcDNA3.1-72Httexon1-eGFP (p72Q) and 150 – 750 nM
GRO or control ODN using 2.5 μl Lipofectamine 2000
(Invitrogen). Forty-eight hours after transfection cells
were viewed to determine the approximate number of
green fluorescent foci using an Olympus IX50 micro-
scope.
Circular dichroism spectroscopy
Circular dichroism spectra of 15 μM oligonucleotide sam-
ples in 10 mM KCl were recorded on an Aviv model 202
spectrometer. Measurements were performed at 24°C
using a 0.1 cm path-length quartz cuvette (Hellma). The
CD spectra were obtained by taking the average of two
scans made at 1 nm intervals from 200 to 320 nm and
subtracting the baseline value corresponding to that of
buffer alone. Spectral data are expressed in units of mil-
lidegree.
PC12 viability assay
Rat pheochromocytoma cells, PC12, were grown in high
glucose DMEM with 10% horse serum and 5% FBS while
under selection with G418 (0.05 mg/mL) and Zeocin (0.1
Inhibition of mutant Htt fragment aggregation by oligonucleotides as measured by FACS Figure 13
Inhibition of mutant Htt fragment aggregation by oligonucleotides as measured by FACS. HEK293 cells were trans-
fected with pcDNA3.1-72Httexon1-eGFP (p72Q) and the specific ODN (HDA, HDG) at the indicated concentrations and the 
degree of aggregation measured by FACS after 48 hours. (A) No plasmid (p72Q); (B) only p72Q, no ODN; (C) p72Q and 1 μM 
HDA; (D) p72Q and 2.5 μM HDA; (E) p72Q and 1 μM HDG; (F) p72Q and 2.5 μMHDG. All ODNs are at final concentrations 
in the cell culture reaction. The magnitude of green fluorescence is measured on the X axis while the number of cells exhibiting 
that degree of fluorescence is depicted on the Y axis.BMC Neuroscience 2006, 7:65 http://www.biomedcentral.com/1471-2202/7/65
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mg/mL) (Invitrogen). This cell line, Htt14A2.6, expresses
a truncated form of expanded repeat Htt exon 1 protein
containing 1–17 amino acids and 103 polyglutamine tract
fused to eGFP. The promoter was induced with murister-
one resulting in the expression of the Htt exon 1 with
expanded 103 CAG polyglutamine (103Q) region. Cells
were seeded at 3 × 104 cells/well on a 24-well plate and
transfected with a ratio of 0.8 μg HDG 20 to 2 μL Lipo-
fectamine 2000 (Invitrogen) depending on the desired
HDG concentration. After a 4-hour treatment, the trans-
fection media was removed, whole media was added for
1-hour, and then the cells were induced using 5 μM muris-
terone for 24 hours. The Promega CellTiter-Glo Lumines-
cent cell viability assay was then used. The control cells
using only Lipofectamine 2000 were counted and plated
at 2 × 104 cells in at least 6 wells of a 96-well plate. The
same volume of cells used in this control at 24-hours, was
used in the following treatments at that time point and
the remaining 48 and 72-hour time points. After the cells
were replated, an equal amount of cell viability substrate
was added to each well, according to protocol. After the
substrate is added, the plate was placed on a rocker for 2
mins then incubated for 10 mins. Finally, the plate was
read 3 times per treatment on a Victor3V 1420 Multilabel
counter and analyzed using the Wallac 1420 software.
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Viability assay of PC12 cells transfected with various HDG concentrations Figure 14
Viability assay of PC12 cells transfected with various HDG concentrations. The PC12 cell line, Htt14A2.6, was trans-
fected with varying amounts of HDG in Lipofectamine 2000. The Promega CellTiter-Glo Luminescent cell viability assay was 
used to analyze the viability of each treatment as a function of time. One control is a mock-transfected cell culture containing 
lipofectamine 2000 but no oligonucleotide; whereas the no treatment control presented here indicates cells that have received 
neitheroligonucleotide nor lipofectamine. Statistics were performed by using the standard deviation on 27 luminescent read-
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